Description

Other Name: SSX1; Protein SSX1; Cancer/testis antigen 5.1; CT5.1; Synovial sarcoma, X breakpoint 1; SSX2; SSX2A; SSX2B; Protein SSX2; Cancer/testis antigen 5.2; CT5.2; Synovial sarcoma, X breakpoint 2; Tumor antigen HOM-MEL-40; SSX3; Protein SSX3;Cancer/testis antigen 5.3; CT5.3; SSX4; SSX4A; SSX4B; Protein SSX4; Cancer/testis antigen 5.4; CT5.4; SSX5; Protein SSX5; SSX6; Putative protein SSX6; SSX7; Protein SSX7; SSX8; Protein SSX8; SSX9; Protein SSX9

Background: The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X. [provided by RefSeq, Jul 2013],